Live Breaking News & Updates on Regulations Of The French Market Authority Autorit

Stay updated with breaking news from Regulations of the french market authority autorit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Strengthening of Pherecydes Pharma's Patent Portfolio with Two New Patents Granted in the United States

(2)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, today announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its
anti-Pseudomonas Aeruginosa and
Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, says:
We are very pleased that the USPTO has granted us these two new patents for our anti-Pseudomonas aeruginosa and anti-E. Coli phages. These two new patents in the world s leading healthcare market greatly expand the geographical areas in which our phages are now protected. This is a further evidence of the relevance of the intellectual property strategy we have implemented. We will continue to protect our champion phages with this now proven strategy. ....

United States , Hong Kong , United Kingdom , Pherecydes Pharma , Philippe Rousseau , Nicolas Merigeau , Dusan Oresansky , Prospectus Directive Of The European Union , Trademark Office , Regulations Of The French Market Authority Autorit , European Parliament , Financial Services , Regulatory News , United States Patent , Pseudomonas Aeruginosa , Charles Fanneau De La Horie , French National Agency , French Monetary , Financial Code , General Regulations , French Market Authority , Des March , Prospectus Directive , European Union , Markets Act , Financial Promotion ,

Resounding Success of Pherecydes Pharma's IPO on the Euronext Growth Market in Paris

Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris
Offer oversubscribed 4 times, with global demand totaling €28.1 million
Capital increase of approximately €8 million, after full exercise of the Extension Clause
Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth
market in Paris.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says:
I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who h ....

United States , France General , United Kingdom , Pherecydes Pharma , Philippe Rousseau , Bpifrance Entreprise , Kostenloser Wertpapierhandel , Nicolas Merigeau , Dusan Oresansky , Entreprise Innovante , Regulations Of The French Market Authority Autorit , European Parliament , Early Access Program , Financial Services , Company Supervisory Board , Prospectus Directive Of The European Union , Document May Not Be Published , Either Directly , Charles Fanneau De La Horie , Executive Board , Global Placement , Extension Clause , Escherichia Coli , Fixed Price Offer , Euronext Growth , Supervisory Board ,